Table I.
Details of the recurrent lesions.
| Hormone receptor | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Patient | Age (years) | ER | PgR | HER2 | Treated site (RT field) | Exposure dose (Gy) | Imaging examination | FDG accumulationa | Tumor size (mm) | Therapeutic effect |
| 1 | 61 | (+) | (−) | (2+) | Parasternal | X 44.0 | PET-CT | 12.0 → 3.6 | 41.0 → 26.0 | PR |
| 2 | 83 | (+) | (−) | (1+) | Lt. breast | X 44.0+E 9.0 | PET-CT | 3.1 → disappearance | 10.0 → disappearance | CR |
| 3 | 46 | (−) | (+) | (1+) | Lt. breast | E 40.0 | PET-CT | 4.4 → 1.9 | 23.0 → disappearance | CR |
| (−) | (+) | (1+) | Lt. rectus abdominis muscle | E 48.0 | PET-CT | 8.9 → disappearance | 33.0 → disappearance | CR | ||
| 4 | 51 | (+) | (+) | (3+) | Rt. breast | E 40.0 | PET-CT | 3.0 → disappearance | 9.0 → disappearance | CR |
| 5 | 64 | (−) | (−) | (3+) | Lt. breast | E 40.0 | PET-CT | 4.3 → disappearance | 23.0 → disappearance | CR |
| 6 | 80 | (+) | (+) | (1+) | Rt. breast | E 32.0 | MRI | No data | 9.0 → disappearance | CR |
| 7 | 80 | (+) | (+) | (1+) | Lt. axilla | X 49.5 | MRI | No data | 7.0 → disappearance | CR |
| 8 | 59 | (+) | (+) | (2+) | Rt. axilla | X 49.5 | PET-CT | 7.0 → disappearance | 18.0→ disappearance | CR |
| 9 | 58 | (+) | (−) | (−) | Rt. supraclavicular LN | E 48.0 | PET-CT | 10.7 → 2.5 | 26.0 →14.0 | PR |
| (+) | (−) | (−) | Rt. cervical LN | E 40.0 | PET-CT | 9.7 → 4.0 | 31.0 →18.0 | PR | ||
| 10 | 66 | (+) | (+) | (−) | Rt. supraclavicular LN | E 48.0 | PET-CT | 1.5 → 4.9 | 15.0 →30.0 | PD |
| 11 | 69 | (−) | (−) | (−) | Lt. supraclavicular LN | X 49.5 | PET-CT | 9.3 → disappearance | 54.0 → disappearance | CR |
| 12 | 63 | (−) | (−) | (3+) | Lt. supraclavicular LN | E 48.0 | PET-CT | 3.6 → disappearance | 13.6 → disappearance | CR |
| 13 | 39 | (−) | (−) | (−) | Lt. pectoralis major muscle | X 49.5 | PET-CT | 7.0 → 5.0 | 27.0 →20.0 | PR |
| 14 | 66 | Unclear | Lt. supraclavicular LN | E 48.0 | PET-CT | No data | 25.0 → disappearance | CR | ||
| 15 | 61 | (−) | (−) | (3+) | Rt. supraclavicular LN | E 48.0 | PET-CT | 9.3 → 3.5 | 16.0 → disappearance | CR |
| (−) | (−) | (3+) | Lt. cervical LN | E 48.0 | PET-CT | 6.5 → 3.3 | 15.0 → disappearance | CR | ||
| 16 | 52 | Unclear | Lt. breast | X 44.0+E 9.0 | PET-CT | 3.0 → disappearance | 10.0 → disappearance | CR | ||
| 17 | 76 | Unclear | Lt. breast | E 48.0 | PET-CT | 5.7 → disappearance | 12.0 → disappearance | CR | ||
| 18 | 59 | (+) | (+) | (3+) | Rt. axilla | X 49.5 | PET-CT | 12.5 → 5.3 | 24.0 → 10.0 | PR |
| (+) | (+) | (3+) | Rt. breast | E 48.0 | PET-CT | 8.0 → disappearance | 23.0 → disappearance | CR | ||
| 19 | 52 | (+) | (−) | (−) | Skin of sinciput | E 48.0 | PET-CT | No data | 10.0 → disappearance | CR |
| 20 | 84 | Unclear | Rt. breast | X 44.0+E 9.0 | PET-CT | No data | 8.0 → disappearance | CR | ||
a
Measured as the maximum standardized uptake value. HER (1+), <10% cells exhibit positive membrane staining; HER (2+), 10–30% cells exhibit positive membrane staining; HER (3+), >30% cells exhibit positive membrane staining; ER, estrogen receptor; PgR, progesterone receptor; HER2, human epidermal growth factor receptor 2; RT, radiation therapy; Rt., right; Lt., left; LN, lymph node; X, X-ray; E, electron beam; PET, positron emission tomography; CT, computed tomography; MRI, magnetic resonance imaging; FDG, fluorodeoxyglucose; CR, complete response; PR, partial response; PD, progressive disease.